ELUTIA INC. (ELUT) Form 8-K — May 14, 2026
Elutia Inc. reported Q1 2026 net sales of $3.1 million, a 6% increase year-over-year, but posted a net loss of $7.5 million compared to $3.9 million in the prior year. The widening loss was primarily driven by a $6.7 million unfavorable swing in other expenses, largely due to a $1.7 million non-cash loss on warrant liability revaluation versus a $5.2 million gain in the previous year. Operationally, the company highlighted significant progress in its core drug-eluting biomatrix business.
Key figures
- Revenue
- 3114000
- Revenue Yoy
- 6%
- Total Assets
- 55209000
- Cash Position
- 28488000
- Shares Outstanding
- 44200000
- Escrow funds
- 8000000
- Gross margin gaap
- 57.9%
- Gross margin adjusted
- 66.5%
- Total cash and escrow
- 36500000
Price after filing
Close on the filing date to close N calendar days later (from $1.04). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.